Kornimate/medical-research-clean huggingface dataset:
raising healthy children: a hybrid trial of the family check-up 4 health in primary care

Conditions: Clinical Trial

Summary: this study is a hybrid implementation-effectiveness trial of the family check-up 4 health (fcu4health), an adapted version of the family check-up, in pediatric primary care. patients will be recruited based on their bmi as documented in the electronic health record (ehr) and randomized to receive the fcu4health or treatment as usual.

the fcu4health is an assessment-driven, motivational interviewing (mi) based, parent training program. parents and children complete a comprehensive assessment, including questionnaire and observation data. the fcu4health coordinator reviews the assessment results with the parents, using mi strategies to create a tailored plan to address family needs. this plan may include referrals to community resources or parenting modules that focus on family management.

Eligibility criteria:
inclusion criteria: * bmi at or above 85% tile for age and gender exclusion criteria: -

Keywords: hybrid implementation effectiveness parent training fidelity cost-effectiveness primary care
exploration of hrqol and urinary outcomes following partial cystectomy

Conditions: Bladder Carcinoma

Summary: this study explores and compares health-related quality of life and urinary outcomes in postoperative partial cystectomy and matched radical cystectomy patients.

primary objectives: i. explore and compare urinary outcomes in postoperative partial cystectomy patients and matched radical cystectomy patients through patient-filled questionnaires. ii. explore and compare health related quality of life in postoperative partial cystectomy and matched radical cystectomy patients using patient-filled questionnaires. iii. explore the relationship of patient-specific characteristics, ranging from demographic characteristics and clinicopathologic characteristics, on variation in hrqol and urinary outcomes among the partial cystectomy and radical cystectomy cohorts. outline: this is an observational study. patients complete questionnaires and have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * currently living partial cystectomy patients in mayo urology's cystectomy registry and patients undergoing radical or partial cystectomy * matched 2:1 living radical cystectomy to partial cystectomy patients * either urothelial or non-urothelial histology exclusion criteria: * partial cystectomy patients that underwent subsequent radical cystectomy
therapy evaluation in patients with minor stroke and large vessel occlusion

Conditions: Stroke, Acute; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Vascular Diseases; Brain Infarction; Nervous System Diseases

Summary: this multicenter registry study, which record the therapy strategy and follows up these acute ischemic stroke (ais) patients with low nihss and large vessel occlusion (lvo), is intended to provide the important data for therapy evaluation and prognostic prediction of the lvo patients with low nihss.

it was reported that about two third of the stoke patients might present with minor or mild stroke symptoms. 20-40% of those minor stroke patients had large vessel occlusion (lvo). ais patients with lvo and low nihss are common and has been associated with early neurological deterioration and worse outcomes. until now, the best therapy strategy for the acute stoke patients with minor stroke and large vessel occlusion is unknown. thus, we sought to (1) explore the potential predictors of acute neurological deterioration and 90-day clinical outcome; (2) and evaluate the best therapy strategy.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older 2. acute ischemic stroke patients of nihss 0-5 with 24 hours after onset 3. proximal intracranial artery occlusion on ncct/cta or mri/mra showing occlusion of the intracranial ica, m1, or proximal m2 vessel 4. baseline aspects ≥6 or infarct core volume of \< 70 on ncct/dwi/ctp 5. pre-mrs≤1 exclusion criteria: 1. any sign of intracranial hemorrhage on baseline ct/mr; 2. seizures at stroke onset 3. baseline blood glucose of \ 22.20 mmol, or platelet count \ 3.0 mg/dl 4. participation in any investigational study in the previous 30 days

Keywords: stroke mechanical thrombectomy proximal intracranial arterial occlusions large vessel occlusion acute neurological deterioration outcome
tranexamic atomized for pediatric post-operative tonsillectomy hemorrhage

Conditions: Hemorrhage, Surgical; Tonsillar Bleeding

Summary: after a child has their tonsils removed, sometimes they might bleed which can be a problem. there is a special mist medicine called nebulized tranexamic acid (txa) that might help stop the bleeding without having to touch the sore spot. if this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.

the study intervention involves administering nebulized tranexamic acid (txa) to pediatric patients with traumatic hemorrhage (pth). the intervention consists of three consecutive doses of nebulized txa. the dosage of nebulized txa is adjusted based on the child's weight. for children weighing more than 25 kg, each dose is 500 mg. for children weighing less than 25 kg, each dose is 250 mg. frequency: the three doses of nebulized txa are administered consecutively over the course of approximately an hour. administration method: nebulized txa is delivered through a nebulizer device. a nebulizer converts the liquid medication into a fine mist or aerosol, which is then inhaled by the patient. this method allows the medication to be delivered directly to the respiratory tract, where it can exert its effect on the bleeding site. delivery setting: the intervention may take place in a clinical setting, such as a hospital or outpatient clinic, where nebulizer devices and medical supervision are readily available. each patient receives three nebulized independent doses of txa in succession. the delivery of the intervention is carried out by healthcare professionals trained in administering nebulized medications.

Eligibility criteria:
inclusion criteria: 1. received a tonsillectomy 2. presents to the ed with secondary\* post-tonsillectomy hemorrhage 3. children between age of 2 to 17 years of age (i.e., before their 18th birthday) \*secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery/pacu). exclusion criteria: 1. known and documented bleeding or clotting disorder. 2. known pregnancy. 3. patients with known hypersensitivity or allergic response to tranexamic acid. 4. parents or guardians who cannot communicate in english or spanish. 5. intubation prior to enrollment. 6. previously enrolled patients.

Keywords: tranexamic acid nebulizer post tonsillectomy hemorrhabe
assessment of patients with drug-resistant temporal lobe epilepsy with eeg extended with intra-auricular electrodes

Conditions: Epilepsy; Focal Epilepsy; Drug Resistant Epilepsy

Summary: the study aims to evaluate the effectiveness of long-term video eeg monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (ieds) in patients with temporal lobe epilepsy (tle) and nontemporal lobe epilepsy (non-tle).

this study is a monocentric observational study aiming to evaluate the effectiveness of long-term video eeg monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (ieds) in patients with temporal lobe epilepsy (tle) and nontemporal lobe epilepsy (non-tle). 30 subjects with drug-resistant focal epilepsy undergoing long-term eeg monitoring as part of the pre-surgical assessment will be included. all patients referred to the uck wum department of neurosurgery for video eeg monitoring will be subject to prescreening. those who, according to prior medical documentation, don't meet exclusion criteria and are likely to meet inclusion criteria will be invited to participate in the study and will undergo an initial assessment in form of a structured interview with a clinician, eeg recordings will be carried out simultaneously using standard eeg equipment (full set of electrodes according to the 10-20 system extended by additional temporal electrodes t9/t10) and the naox in-ear eeg system device. eeg monitoring will take place for 5 days of hospitalization according to the standard protocol of the video-eeg laboratory of the department of neurosurgery, csk uck, medical.

Eligibility criteria:
inclusion criteria: * age \> 18 years * diagnosis of drug-resistant epilepsy * sufficient level of cooperation to use of the naox in-ear eeg system * providing informed consent to participate in the study exclusion criteria: * presence of skull bone defects, e.g. after prior neurosurgery * presence of comorbidities that may significantly affect the resting eeg * medical history strongly suggestive of psychogenic nonepileptic attacks

Keywords: in-ear eeg eeg epilepsy focal epilepsy drug resistant epilepsy intra-auricular eeg
the effect of sugammadex given based on ideal, actual or adjusted body weight on reversal of rocuronium.

Conditions: Muscle Relaxation

Summary: the aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.

the aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight. reversal time: time from administration of sugammadex to train of four (tof) ratio ≥ 0.9 will be used as primary outcome. time need for extubation (time from administration of sugammadex to extubation), and duration of stay in post anesthesia care unit (pacu), will be used as secondary outcome.

Eligibility criteria:
inclusion criteria: * patients older than 18 years and under 45 years, * body mass index ≥ 40 kg/m2, with indication of bariatric surgery exclusion criteria: * patients with comorbid including: neuromuscular disease, renal impairment, and patients with difficult airway were excluded from this study.

Keywords: sugammadex morbidly obese patients bariatric surgery neuromuscular blockade
refractive outcomes after cataract surgery in eyes with pseudoexfoliation syndrome

Conditions: Refractive Errors; Cataract

Summary: to evaluate the refractive outcomes of cataract surgery in pex syndrome and determine which of the commonly used iol formulas (srk/t, barrett universal ii and hill-rbf) is the best in predicting postoperative refractive outcomes in pex.

the primary outcome measure was to compare refractive outcomes (mae, medae, percentage of eyes within certain range of prediction error) in pex and control eyes. the secondary outcome measure was to determine whether any of iol power prediction formulas (srk/t, barrett universal ii and hill-rbf) is more precise for these challenging eyes.

Eligibility criteria:
inclusion criteria: * senile cataract with/without pex exclusion criteria: * corneal pathology * glaucoma, * corneal astigmatism greater than 2.0 diopters (d), * previous eye surgery or subjects with decreased vision due to other reasons than cataract (e.g., exudative age-related macular degeneration (amd), proliferative diabetic retinopathy, inflammatory eye diseases), * intraoperative complications, * postoperative corrected distance visual acuity (cdva) worse than 20/40, * axial length below 21 mm and above 25 mm, * dense cataracts or poor fixation requiring ultrasound biometry * eyes with manifest iridophacodonesis and those in which a capsular tension ring was inserted

Keywords: pseudoexfoliation phacoemulsification cataract surgery iol power calculation formulas
assessment of primary care providers' knowledge and beliefs regarding gout management

Conditions: Gout

Summary: this is a questionnaire study aimed at learning about physicians' views on the treatment of gout.

we seek to assess the knowledge, beliefs and reported treatment practices of primary care physicians with regard to gout. specifically, we will: * assess the knowledge and beliefs with regard to acute and chronic gout management based on published treatment recommendations. * characterize the individuals who have knowledge deficits in terms of age, specialty, number of patients seen with gout, and practice setting. * assess the reported treatment practices of primary care physicians for the acute and chronic management of gout.

Eligibility criteria:
inclusion criteria: * practicing primary care practitioner, either in family medicine or internal medicine, * must be 18 years of age or older exclusion criteria: * does not meet inclusion criteria

Keywords: gout chronic condition management gout management
antithrombotic therapy in patients undergoing cied surgery - hematoma no more registry

Conditions: Device Related Infection; Antithrombotic Drugs; Cardiac Arrhythmia; Surgery--Complications; Hematoma

Summary: hundreds of thousands patients undergo implantation or replacement of cardiac implantable electronic devices (cieds) annually in europe, and up to 50% of these subjects receive antiplatelet agents or oral anticoagulants. antithrombotic therapy increases the risk of developing pocket hematoma which in turn is associated with an increased risk of potentially fatal device-related infections when clinically significant. aim of the registry is to retrospectively (pilot local registry in tuscany) and prospectively (multicenter national registry in italy) investigate the different strategies for the management of antithrombotic therapy and the related complication rates (1-month and 12-months) in patients undergoing cied surgery in a real-world setting. the registry will also provide data on the economic impact of different management strategies and complications.


Eligibility criteria:
inclusion criteria: * patients with standard indications to cied surgery being treated with antiplatelet agents and/or anticoagulants (any commercially available device or approved and marketed drug can be included). * patients able to provide written informed consent * patients willing to attend the planned follow-up visits exclusion criteria: * patient with life expectancy less than 12 months as per investigator's judgement
venous thromboembolism and bleeding risk in patients with esophageal cancer

Conditions: Venous Thromboembolism; Esophagus Cancer; Bleeding; Chemotherapy Effect

Summary: this study aims to assess the 6- and 12-month venous thromboembolism (vte) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. additionally, the predictive value of the khorana score and several other vte and bleeding prediction scores and risk factors will be evaluated.

patients with cancer are at high risk of venous thromboembolism (vte), including deep-vein thrombosis and pulmonary embolism. for cancer patients receiving chemotherapy the incidence of vte is even higher. several predictive models were previously developed to identify and justify thromboprophylaxis for cancer patietns who are at highest risk of vte, like the khorana and protecht score. the khorana score is a risk-stratification tool to select patients at high risk of vte for thromboprophylaxis. the protecht score takes cisplatin-based chemotherapy into account in addition of the khorana score. thereby, the incidence of bleeding and vte in patients with esophageal cancer is not clear. this study aims to assess the 6- and 12-month venous thromboembolism (vte) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. additionally, the predictive value of the khorana score and several other vte and bleeding prediction scores and risk factors will be evaluated.

Eligibility criteria:
inclusion criteria: * esophageal cancer patients * receiving chemotherapy * age at least 18 years old exclusion criteria: - death \<3 months after cancer diagnosis (baseline)
standardized ceus algorithms for diagnosis of hcc - prospective german multicenter study

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma, Intrahepatic; Liver Cirrhosis; Liver Cancer; Liver Neoplasms; Liver Diseases

Summary: aim of this prospective national multicenter study is to improve standardization of contrast-enhanced ultrasound (ceus) in the non-invasive diagnosis of hepatocellular carcinoma (hcc) in high-risk patients. the study is funded by the german society for ultrasound in medicine (degum).

to date, ceus criteria for non-invasive diagnosis of hcc include arterial phase hyperenhancement, followed by contrast washout in the portal venous or late phase. we would like to investigate the following points: 1. whether arterial hyperenhancement alone is sufficient for the definite diagnosis of hcc in cirrhosis with ceus 2. whether a further clearly-defined point of assessment in the late phase after 4-6 minutes is of additional diagnostic value in focal liver lesions showing no contrast washout after 3 minutes 3. diagnostic value of ceus-based standardised diagnostic algorithms (esculap = erlanger synopsis of contrast enhanced ultrasound for liver lesion assessment in patients at risk; ceus li-rads = contrast enhanced ultrasound liver imaging reporting and data system) for non-invasive diagnosis of hcc in high-risk patients (diagnostic accuracy, interobserver-variability, feasability in clinical routine).

Eligibility criteria:
inclusion criteria: * high risk for hcc * focal liver lesion on b-mode ultrasound exclusion criteria: * pre-treated hcc lesion * systemic therapy for hcc (sorafenib, regorafenib and others)

Keywords: contrast-enhanced ultrasound non-invasive diagnosis focal liver lesion liver cirrhosis standardised diagnostic algorithm intrahepatic cholangiocellular carcinoma esculap ceus li-rads imaging hepatocellular carcinoma mri diagnostic accuracy interobserver agreement erlanger synopsis of ceus for liver lesion assessment in patients at risk ceus liver imaging reporting and data system
rsv burden in outpatient settings

Conditions: RSV Infection; Children, Only; Outpatient; Bronchiolitis; Otitis Media; Pneumonia

Summary: strengthening outpatient low respiratory tract infection surveillance to document the burden of respiratory syncytial virus (rsv)

the study protocol is designed with three key components: 1. build on existing pari outpatient syndromic surveillance by adding laboratory multiplex testing of lrti samples (rsv, influenza, sars-cov-2) 2. follow all bronchiolitis through the pari rwe database and document "patient journey" for 5 years after first medical visit 3. review the electronic pari data of three previous seasons in order to document the impact of lrti attributable to rsv in children \< 2 years in france prior to enhanced surveillance

Eligibility criteria:
inclusion criteria: * children under 24 months of age (≤) * one of the holders of parental authority signed the consent * patient affiliated to a social security scheme (social security or universal medical coverage) * first episode of bronchiolitis defined by * age ≤24 months * at least one symptom from group a and one symptom from group b group a (one or more) * fever \>38 °c * cough * otalgia * nasal congestion * rhinorrhea * coryza * dysphagia group b (one or more) * whistling * crackles * rales * decrease in respiratory noise * shortness of breath * dyspnea * or acute purulent otitis media (paradise criteria) or otorrhea. * or pneumonia defined by the presence of opacity of parenchymal condensation and/or pleural effusion on chest x-ray associated with fever exclusion criteria: * age \>24 months * refusal by one of the parents * not affiliated to a social security system

Keywords: rsv children bronchiolitis otitis pneumonia
use of cone beam kilovoltage imaging in patients receiving radiation therapy for head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: to evaluate the use of cone beam computed tomography in treating head and neck to hopefully reduce side effects

the general purpose of this study is to evaluate kilovoltage (kv) imaging, specifically the cone-beam ct (cbct) scan device, to assess the accuracy of radiation therapy treatment delivery for patients with head and neck neoplasms

Eligibility criteria:
inclusion criteria: * any patient receiving radiation therapy for a head and neck tumor assigned to the new elekta synergy linare accelerator exclusion criteria: * na

Keywords: kilovoltage imaging cone-beam ct cbct radiation therapy head and neck neoplasms
pathophysiologic changes in the respiratory system after fire smoke inhalation

Conditions: Bronchial Asthma

Summary: fire smoke inhalation may contribute to intrabronchial inflammation, airway obstruction and impaired gas exchange. in this study the investigators will examine if the scope of inhalation injury can be assessed soon after hospital admission based on clinical markers, biochemical markers, peak expiratory flow (pef), spirometry and bronchoscopy. at 6 months a lung function test and metacholine test will be performed to examine whether patients have developed increased bronchial hyperreactivity (asthma) or not after the initial fire smoke exposure.

fire smoke inhalation may contribute to intrabronchial inflammation, airway obstruction and impaired gas exchange. the scope of injury in fire smoke victims ranges from cough and minor airway irritation to severe respiratory failure and long term mechanical ventilation in the intensive care unit. some patients with high hbco-levels are also treated with hyperbaric oxygen therapy. in this study the investigators will examine if the scope of inhalation injury can be assessed soon after admission based on clinical markers, biochemical markers, peak expiratory flow (pef), spirometry and bronchoscopy. the clinical effect of fiberoptic bronchoscopy after severe smoke inhalation will also be examined. at 6 months a lung function test and metacholine test will be performed to examine whether they have developed asthma/increased bronchial hyperreactivity or not after the initial fire smoke exposure. lab staff (flowcytometer and cytokine analysis) are unaware of patient identity and whether the patient is a smoke-exposed patient or a healthy volunteer in the control group of non-exposed persons.

Eligibility criteria:
inclusion criteria: * fire smoke exposed patient * \> 18 years of age * admitted to hospital exclusion criteria: * \< 18 years of ager * trauma patient control group (healthy volunteers/hospital staff): * \> 18 years of age * non-smoker * no exposure to fire smoke